Pharmaceutical Companies

We work with pharmaceutical companies in a number of different business units to help them better understand, mitigate, navigate, and commercialize based on comparative safety issues in both clinical and approved drugs.

Pharmacovigilance and Epidemiology

While internal data has long been the gold standard for PV signal detection, your role is quickly changing. Make sure you are the first to identify, manage and track potential safety signals using proven, peer-reviewed processes and analytic tools based on curated, harmonized, and reliable clinical and real world data.

Market Access

Help payers make decisions with comparative evidence. Demonstrate superior efficacy and safety profiles using annotated data from curated clinical trial results and independent, unbiased real world data. Use data that is featured on AMCP’s eDossier platform and peer reviewed in the Journal of Managed Care and Specialty Pharmacy.

Health Economics and Outcomes Research

Health economic models are only as good as the data that goes into them. Demonstrate commitment to providing fully transparent budget impact forecasts using a trusted source of independent, real world data.

Brand Teams and Product Marketing

Understanding emerging evidence trends for both your products and competitor products to ensure better planning and positioning. Leverage new and highly accurate drug data to compare and better understand brand trajectory.

Business Development and Licensing

Thorough due diligence for strategic investing and licensing partnerships includes analysis of comparable evidence. Emerging evidence trends and comparative assessment can appropriately position the risks and advantages of a particular candidate in today’s market.

HEOR at Lundbeck Pharmaceuticals

Lundbeck was preparing the launch of a new antipsychotic into a competitive market where perception is that the tolerability of treatments is adequately managed with atypical antipsychotics (AAPs). The study examined the FDA Adverse Event Reporting System (FAERS) in order to establish the level and costs of post-marketing, AAP-related adverse events (AEs) reported since 2008. The study concluded that while AAPs were expected to have a reduced side effect burden compared to older antipsychotics, patients still report higher than expected AE rates and these AEs may have costly implications.